The report cited one man who completed a 14-question intake on Hims.com and received a bottle of finasteride pills days later. However, after taking the medicine he experienced weird symptoms ...

I think Hims & Hers Health has achieved "escape velocity", with a 95%+ increase year-over-year in Q4 2024 and expected 56%-63% growth in 2025, net of GLP-1 issues. The market overreacted to HIMS ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.

Hims & Hers Health (HIMS) stock enjoyed a 10% jump in price last week on news that the company plans to continue offering compounded versions of Ozempic and Wegovy. This approach is in response to ...

Hims & Hers is set to continue offering weight-loss pills and personalized weight-loss support, including nutrition plans and coaching. Outside of weight-loss care, the company saw its subscriber ...

Hims & Hers Health, Inc. (HIMS) shares rallied 5.7% in the last trading session to close at $34.75. This move can be attributable to notable volume with a higher number of shares being traded than ...

Hims & Hers Health Inc. (NYSE:HIMS) Hims & Hers rallied by 5.72 percent on Friday to finish at $34.75 apiece as investors loaded up on its shares despite the lack of catalysts to boost investing ...

The knockoff surge was led by Hims & Hers Health, the telehealth firm that began selling the drugs last spring.

Hims & Hers Health (NYSE: HIMS) stock jumped 2.2% through 10:45 a.m. ET Monday after Morgan Stanley analyst Craig Hettenbach delivered some good news for the mail-order drugs stock. Citing third ...

Hims & Hers reported its Q4 earnings this week. The company is growing quickly but faces a potential legal threat to its weight loss drug program. It is guiding for margin expansion and fast ...